To conclude, ASO FOXP3 targeting of Tregs in cancer samples was accompanied by decreased number of Tregs, reduced mRNA FOXP3 expression, lower amounts of FOXP3 in Tregs that still expressed FOXP3, decreased CD39 expression in those Tregs, and downregulation of exhaustion markers on non-Treg cells, along with their enhanced expression of inflammatory cytokines. This evidence concerns the gene FOXP3 and cancer.